Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China (mainland).
Guangzhou Institute of Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).
Med Sci Monit. 2021 Mar 24;27:e929575. doi: 10.12659/MSM.929575.
BACKGROUND Gastrointestinal stromal tumors (GISTs), which originate from interstitial cells of Cajal (ICCs), are one of most common mesenchymal tumors of the gastrointestinal tract. This study explored the impact of ICCs and immunological markers on GIST risk. MATERIAL AND METHODS A total of 122 patients diagnosed with GISTs who underwent surgery were recruited for the study. Demographic and clinical information, including modified NIH criteria, sex, age, tumor site, and tumor size, of all patients were collected. GIST risk was assessed using the modified NIH risk classification for primary GISTs. Paraffin-embedded GIST specimens were evaluated by hematoxylin-eosin staining and ICCs immunohistochemistry. RESULTS According to the modified NIH criteria, most GIST cases (44 cases, 36.07%) were at very low risk. Females had greater incidence of high-risk GISTs (P<0.05). The mean age at GIST diagnosis was 58.69±9.90 years and had no impact on GIST risk (P>0.05). Most GISTs were located in the stomach (87 cases, 71.73%), and the size of the tumors varied (0.5-20 cm). CD117/c-kit and CD34 were specific immuno-markers for ICCs and GIST. Most patients with GIST were CD117-positive (115 cases, 94.26%), 111 cases (90.98%) were CD34-positive, and 109 cases (89.34%) were positive for both CD117/c-kit and CD34. With increasing GIST risk, CD117 (also named c-k0it) and CD34 expression levels increased, as well as the number of ICCs (all P<0.05). CONCLUSIONS ICCs have a great impact on GISTs incidence. CD117/c-kit and CD34 expression, as well ICCs levels, appear to affect GIST risk.
胃肠道间质瘤(GISTs)起源于卡哈尔间质细胞(ICCs),是胃肠道最常见的间叶性肿瘤之一。本研究探讨了 ICCs 和免疫标志物对 GIST 风险的影响。
共招募了 122 例接受手术治疗的 GIST 患者进行研究。收集所有患者的人口统计学和临床资料,包括改良 NIH 标准、性别、年龄、肿瘤部位和肿瘤大小。采用改良 NIH 原发性 GIST 风险分类评估 GIST 风险。通过苏木精-伊红染色和 ICCs 免疫组织化学评估石蜡包埋的 GIST 标本。
根据改良 NIH 标准,大多数 GIST 病例(44 例,36.07%)为极低危。女性高危 GIST 发生率更高(P<0.05)。GIST 诊断时的平均年龄为 58.69±9.90 岁,与 GIST 风险无关(P>0.05)。大多数 GIST 位于胃(87 例,71.73%),肿瘤大小不一(0.5-20cm)。CD117/c-kit 和 CD34 是 ICCs 和 GIST 的特异性免疫标志物。大多数 GIST 患者 CD117 阳性(115 例,94.26%),111 例(90.98%)CD34 阳性,109 例(89.34%)CD117/c-kit 和 CD34 均阳性。随着 GIST 风险的增加,CD117(也称为 c-kit)和 CD34 的表达水平以及 ICCs 的数量均增加(均 P<0.05)。
ICCs 对 GISTs 的发病有很大影响。CD117/c-kit 和 CD34 的表达以及 ICCs 水平似乎影响 GIST 风险。